Switzerland · 
What does Novartis Venture Fund invest in?
Novartis Venture Fund invests most often at Series B and Series A (68% of the rounds on record), in sectors such as Molecules, Drug and Pharma.
Novartis Venture Fund highlights
- 01
4 cheques in the last 12 months
- 02
Mostly Series B and Series A: 68% of its rounds
- 03
Sole investor in 1 rounds, median $1.7M
- 04
14 exits from the portfolio
What they do
The Novartis Venture Fund was created to foster innovation, drive significant patient benefit, and generate superior returns by nurturing and investing in innovative life science companies.From their own website
- Type
- Corporate VC (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- MoleculesDrugPharma
- Based in
- Cambridge, Switzerland
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first153 appearances
- 2026
3 rounds
- Jul
- Apr
- Jan
- 2025
2 rounds
- Dec
- Sept
- 2024
1 round
- Mar
- 2023
1 round
- Oct
- 2022
1 round
- Mar
- 2019
4 rounds
- Nov
- Sept
- Aug
- Jul
- 2017
3 rounds
- May
- May
- Jan
- 2016
1 round
- Sept
- 2015
13 rounds
- Oct
- Sept
- Jul
- Jul
- Jun
- Jun
- May
- Apr
- Mar
- Mar
- Feb
- Feb
- Jan
- 2014
18 rounds
- Dec
- Nov
- Oct
- Oct
- Oct
- Oct
- Oct
- Aug
- Aug
- May
- May
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 15 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Exits from the portfolio
Companies it backed that were later bought or listed14 in all
Immune Targeting SystemsBought by VaxinUndisclosedFeb 2015
Alios BioPharmaBought by Johnson & Johnson$1.8BSept 2014
CovagenBought by CilagUndisclosedAug 2014
PTC TherapeuticsListed$125MJun 2013
LigoCyte PharmaceuticalsBought by Takeda Pharmaceutical$60MOct 2012
IntellikineBought by Takeda Pharmaceutical$310MDec 2011
EraGen BiosciencesBought by Luminex$34MJun 2011
Foldrx PharmaceuticalsBought by PfizerUndisclosedSept 2010
Intradigm CorporationBought by Silence TherapeuticsUndisclosedDec 2009
OmerosListedUndisclosedOct 2009
VisiogenBought by Abbott Labs$400MSept 2009
Ablation FrontiersBought by MedtronicUndisclosedFeb 2009
Amphora DiscoveryBought by NanosynUndisclosedJul 2008
Glycart Biotechnology AGBought by RocheUndisclosedJul 2005
An exit counts when it came after the firm's first round in the company. From historical deal records.